Term
| Adenosine(Adenocard)-Class |
|
Definition
| Antidysrhythmic used to treat SVT's / PSVT |
|
|
Term
| Adenosine(Adenocard)-Action |
|
Definition
| Decreases conduction of the electrical impulse through the AV node |
|
|
Term
| Adenosine(Adenocard)-Indication |
|
Definition
| Paroxysmal Supraventricular Tachycardia (PSVT) |
|
|
Term
| Adenosine(Adenocard)-Side Effects |
|
Definition
| Facial flushing; headache; shortness of breath; dizziness; nausea |
|
|
Term
| Adenosine(Adenocard)-Dosage |
|
Definition
| 6 mg fast IVP in medication administration port closest to patient, followed by 10 cc rapid flush IVP; if no change: 12 mg fast IVP; 12 mg dose may be repeated once if necessary for a total of 30 mg |
|
|
Term
| Albuterol (Proventil/Ventolin)-Class |
|
Definition
| Sympathomimetic (beta2 selective) |
|
|
Term
| Albuterol (Proventil/Ventolin)-Action |
|
Definition
| Acts on the beta2-adrenergic receptors causing relaxation of bronchial smooth muscles, thus causing bronchodilation |
|
|
Term
| Albuterol (Proventil/Ventolin)-Indication |
|
Definition
| Reversible bronchospasms associated with astham or COPD |
|
|
Term
| Albuterol (Proventil/Ventolin)-Precautions |
|
Definition
|
|
Term
| Albuterol (Proventil/Ventolin)-Side Effects |
|
Definition
| Palpitations; anxiety; headache; dizziness; sweating |
|
|
Term
| Albuterol (Proventil/Ventolin)-Dosage |
|
Definition
| 2.5 mg in 2.5 mL normal saline solution over 5-15 minutes via nebulizer |
|
|
Term
| Amiodarone HCL (Cordarone)-Class |
|
Definition
|
|
Term
| Amiodarone HCL (Cordarone)-Action |
|
Definition
| Prolongs action potential and refractory period; Slows sinus rate; increases PR and QT intervals; decreases peripheal vascular resistance |
|
|
Term
| Amiodarone HCL (Cordarone)-Indications |
|
Definition
| Dysrhythmias such as V-Tach and V-Fib |
|
|
Term
| Amiodarone HCL (Cordarone)-Contraindications |
|
Definition
|
|
Term
| Amiodarone HCL (Cordarone)-Side Effects |
|
Definition
| Hypotension; nausea; fatigue; ventricular ectopic beats |
|
|
Term
| Amiodarone HCL (Cordarone)-Dosage |
|
Definition
| Cardiac arrest: 300 mg IVP; may be repeated at 150 mg IVP Dysrhythmia w/ pulse: 150 mg IV over 10 mins |
|
|
Term
|
Definition
| An analgesic, anti-inflammatory, antipyretic, and antiplatelet |
|
|
Term
|
Definition
| Inhibits platelet aggregation |
|
|
Term
| Aspirin (ASA)-Indications |
|
Definition
| Acute coronary syndrome, unstable angina |
|
|
Term
| Aspirin (ASA)-Precautions |
|
Definition
|
|
Term
| Aspirin (ASA)-Side Effects |
|
Definition
| Nausea; vomiting; wheezing |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Parasympatholytic (anticholinergic) |
|
|
Term
|
Definition
| Blocks acetylcholine receptors, thus inhibiting parasympathetic stimulation and increasing heart rate |
|
|
Term
| Atropine Sulfate-Indications |
|
Definition
| Symptomatic bradycardias, Asystole, PEA with absolute bradycardia, organohosphate or nerve gas poisoning |
|
|
Term
| Atropine Sulfate-Side Effects |
|
Definition
| Palpitations; dizziness; anxiety; dry mouth; pupils dilated; blurred vision |
|
|
Term
|
Definition
| Bradycardia: 0.5 mg fast IVP; may be repeated once Asystole/PEA: 1 mg fast IVP every 3-5 minutes to max of 3 mg Organophosphate poisoning: 2 mg fast IVP every 5 minutes; titrate until secretions subsides |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Increases myocardial contractile force |
|
|
Term
| Calcium Chloride-Indications |
|
Definition
| Acute hyperkalemia or hypocalcemia; Calcium channel blocker overdose; Abdominal muscle spasm associated with neurotoxins |
|
|
Term
| Calcium Chloride-Contraindications |
|
Definition
| Patients receiving digitalis |
|
|
Term
| Calcium Chloride-Side Effects |
|
Definition
| Dysrhythmias; hypotension |
|
|
Term
|
Definition
| 2-4 mg/kg of a 10% solution; may be repeated in 10 minute intervals |
|
|
Term
| Calcium Chloride-PCEMS Dosage |
|
Definition
| Calcium channel blocker overdose: 1 g IV |
|
|
Term
| Calcium Chloride-Pedi Dosage |
|
Definition
| Calcium channel blocker overdose: 0.3 mg/kg IV over 2 minutes |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Rapidly increase blood glucose level |
|
|
Term
| Dextrose (50%)-Indication |
|
Definition
|
|
Term
| Dextrose (50%)-Side Effects |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Tranquilizer (benzodiazepine) |
|
|
Term
|
Definition
| Binds to GABA Type A receptors, potentiating their effects in the brain, thus causing sedation |
|
|
Term
| Diazepam (Valium)-Indications |
|
Definition
| Seizures; Premedication before cardioversion; Acute anxiety states |
|
|
Term
| Diazepam (Valium)-Precautions |
|
Definition
| Do not mix with other drugs because of possible precipitation problems |
|
|
Term
| Diazepam (Valium)-Side Effects |
|
Definition
| Drowsiness; hypotension; respiratory depression and apnea |
|
|
Term
|
Definition
| Status epilepticus: 5-10 mg IV Acute Anxiety: 2-5 mg IM or IV Premedication before cardioversion: 5-15 mg slow IVP |
|
|
Term
| Diazepam (Valium)-PCEMS Dosage |
|
Definition
| Seizure: 5 mg increments slow IVP; titrated to patient response or to max of 10 mg or if no IV 5 mg IM or 10 mg rectal Premedication before cardioversion: 5 mg slow IVP |
|
|
Term
| Diltiazem (Cardizem)-Class |
|
Definition
|
|
Term
| Diltiazem (Cardizem)-Actions |
|
Definition
| Slows conduction through the AV node; Causes vasodilation; Decreases rate of ventricular response; Decreases myocardial oxygen demand |
|
|
Term
| Diltiazem (Cardizem)-Indication |
|
Definition
| Rapid ventricular rates associated with atrial fibrillation and flutter/PSVT |
|
|
Term
| Diltiazem (Cardizem)-Contraindications |
|
Definition
| Hypotension; Wide-complex tachycardia |
|
|
Term
| Diltiazem (Cardizem)-Side Effects |
|
Definition
| Nausea and vomiting; hypotension; dizziness |
|
|
Term
| Diltiazem (Cardizem)-Dosage |
|
Definition
| 0.25 mg/kg bolus (typicaly 20 mg) IV over 2 minutes, followed by maintenance infusion of 5-15 mg/hr |
|
|
Term
| Diphenhydramine (Benadryl)-Class |
|
Definition
|
|
Term
| Diphenhydramine (Benadryl)-Action |
|
Definition
| Blocks histamine receptors |
|
|
Term
| Diphenhydramine (Benadryl)-Indications |
|
Definition
| Allergic reaction and anaphylaxis / Dystonic reactions due to phenothiazines |
|
|
Term
| Diphenhydramine (Benadryl)-Side Effects |
|
Definition
| Sedation; blurred vision; headache; palpitations |
|
|
Term
| Diphenhydramine (Benadryl)-Dosage |
|
Definition
|
|
Term
| Diphenhydramine (Benadryl)-PCEMS Dosage |
|
Definition
| 1 mg/kg IV or IM to max of 50 mg |
|
|
Term
| Dopamine (Intropin)-Class |
|
Definition
| Sympathomimetic / Vasopressor and a naturally occuring catecholamine |
|
|
Term
| Dopamine (Intropin)-Actions |
|
Definition
| Acts on both alpha and beta adrenergic receptors, thus having a positive inotropic (contratility) and chronotropic (rate) effect on the heart, causes peripheral vasoconstriction |
|
|
Term
| Dopamine (Intropin)-Indication |
|
Definition
| Symptomatic bradycardia (second-line after atropine); Cardiogenic shock |
|
|
Term
| Dopamine (Intropin)-Contraindications |
|
Definition
| Active hemorrhage / tachydysrhythmias |
|
|
Term
| Dopamine (Intropin)-Side Effects |
|
Definition
| Ventricular tachydysrhythmias; palpitations |
|
|
Term
| Dopamine (Intropin)-Dosage |
|
Definition
| Initial dose: 2-20 mcg/kg/min IV drip; titrated to maintain systolic B/P > 90 mmHG Method: 400 mg should be place in 250 mL of D5W, giving a concentration of 1600 mg/mL |
|
|
Term
| Epinephrine (Adrenalin) 1:1000 (1mg/1mL)-Class |
|
Definition
|
|
Term
| Epinephrine (Adrenalin) 1:1000 (1mg/1mL)-Actions |
|
Definition
| Increases heart rate, automticity, and contractile force; Increases systemic vascular resistance; Causes bronchodilation |
|
|
Term
| Epinephrine (Adrenalin) 1:1000 (1mg/1mL)-Indications |
|
Definition
| Bronchospasm associated wth asthma or allergic reaction; Allergic reaction |
|
|
Term
| Epinephrine (Adrenalin) 1:1000 (1mg/1mL)-Contraindications |
|
Definition
| Hypertension / Pregnancy / Tachydysrhythmias |
|
|
Term
| Epinephrine (Adrenalin) 1:1000 (1mg/1mL)-Side Effects |
|
Definition
| Palpitations; tachydysrhythmias; anxiety; tremors; headaches; nausea; vomiting |
|
|
Term
| Epinephrine (Adrenalin) 1:1000 (1mg/1mL)-Dosage |
|
Definition
|
|
Term
| Epinephrine (Adrenalin) 1:1000 (1mg/1mL)-PCEMS Dosage |
|
Definition
|
|
Term
| Epinephrine (Adrenalin) 1:10,000 (1mg/10mL)-Class |
|
Definition
| Sympathomimetic and a catecholamine secreted by the adrenal medulla in response to sympathetic stimulation |
|
|
Term
| Epinephrine (Adrenalin) 1:10,000 (1mg/10mL)-Actions |
|
Definition
| Increases heart rate, automaticity, and contractile force / Increases systemic vascular resistance / Causes bronchodilation |
|
|
Term
| Epinephrine (Adrenalin) 1:10,000 (1mg/10mL)-Indications |
|
Definition
| Allergic reaction / Anaphylactic shock / Cardiac arrest / Symptomatic bradycardia |
|
|
Term
| Epinephrine (Adrenalin) 1:10,000 (1mg/10mL)-Contraindications |
|
Definition
| Hypertension / Pregnancy / Tachydysrhythias |
|
|
Term
| Epinephrine (Adrenalin) 1:10,000 (1mg/10mL)-Side Effects |
|
Definition
| Palpitations; tachydysrhythmias; anxiety; tremors; headache; nausea; vomiting |
|
|
Term
| Epinephrine (Adrenalin) 1:10,000 (1mg/10mL)-Dosage |
|
Definition
| Cardiac arrest: 1 mg IV every 3-5 min Severe anaphylaxis: 0.3-0.5 mg IV |
|
|
Term
| Epinephrine (Adrenalin) 1:10,000 (1mg/10mL)-PCEMS Dosage |
|
Definition
| Cardiac arrest: 1 mg IV every 3-5 min Severe anaphylaxis: 0.5 mg IV |
|
|
Term
| Etomidate (Amidate)-Class |
|
Definition
|
|
Term
| Etomidate (Amidate)-Action |
|
Definition
| Produces a rapid induction of anesthesia |
|
|
Term
| Etomidate (Amidate)-Indication |
|
Definition
|
|
Term
| Etomidate (Amidate)-Side Effects |
|
Definition
| Myoclonic skeletal muscle movement |
|
|
Term
| Etomidate (Amidate)-Dosage |
|
Definition
| 0.1-0.3 mg/kg IV over 15-30 seconds |
|
|
Term
| Etomidate (Amidate)-PCEMS Dosage |
|
Definition
|
|
Term
| Fentanyl Citrate (Sublimaze)-Class |
|
Definition
|
|
Term
| Fentanyl Citrate (Sublimaze)-Action |
|
Definition
| Central nervous system depressant / Decreases sensitivity to pain |
|
|
Term
| Fentanyl Citrate (Sublimaze)-Indications |
|
Definition
| Severe pain; Adjunct to RSI/sedation; Maintenance of analgesia |
|
|
Term
| Fentanyl Citrate (Sublimaze)-Precautions |
|
Definition
| Respiratory depression / Hypotension |
|
|
Term
| Fentanyl Citrate (Sublimaze)-Side Effects |
|
Definition
| Dizziness; nausea; altered level of consciousness |
|
|
Term
| Fentanyl Citrate (Sublimaze)-Dosage |
|
Definition
|
|
Term
| Fentanyl Citrate (Sublimaze)-PCEMS Dosage |
|
Definition
| Pain management: titrate up to 2 mcg/kg slow IVP; max of 500 mcg RSI: 6 mcg/kg IV |
|
|
Term
|
Definition
|
|
Term
| Furosemide (Lasix)-Action |
|
Definition
| Inhibits reabsorption of sodium chloride in the Loop of Henle in the kidneys, thus reducing absorption of water |
|
|
Term
| Furosemide (Lasix)-Indications |
|
Definition
| Pulmonary edema in the presence of CHF |
|
|
Term
| Furosemide (Lasix)-Contraindications |
|
Definition
| Pregnancy / Dehydration / Hypotension |
|
|
Term
| Furosemide (Lasix)-Dosage |
|
Definition
|
|
Term
|
Definition
| Hormone (antihypoglycemic agent) |
|
|
Term
|
Definition
| Causes a breakdown of glycogen (stored in liver) to glucose and inhibits the synthesis of glucose to glycogen, thus increasing blood glucose levels; Exerts a positive inotropic action on the heart |
|
|
Term
|
Definition
| Hypoglycemia / Beta-blocker overdose |
|
|
Term
|
Definition
| IV: 0.25-0.5 unit IM: 1 mg |
|
|
Term
|
Definition
| Hypoglycemia: 1 mg IM Asystole with b-blocker overdose: 2 mg IV |
|
|
Term
| Haloperidol (Haldol)-Class |
|
Definition
| Major tranquilizer (butyrophenone) |
|
|
Term
| Haloperidol (Haldol)-Actions |
|
Definition
| Blocks dopamine receptors in brain responsible for mood and behavior |
|
|
Term
| Haloperidol (Haldol)-Indications |
|
Definition
|
|
Term
| Haloperidol (Haldol)-Contraindications |
|
Definition
| Should not be administered in the presence of other sedatives |
|
|
Term
| Haloperidol (Haldol)-Side Effects |
|
Definition
| Physical and mental impairment |
|
|
Term
| Haloperidol (Haldol)-Dosage |
|
Definition
|
|
Term
| Haloperidol (Haldol)-PCEMS Dosage |
|
Definition
| 5 mg IM if < 60 kg 10 mg IM if > 60 kg |
|
|
Term
| Ipratropium Bromide (Atrovent)-Class |
|
Definition
| Anticholinergic, bronchodilator, parasympatholytic |
|
|
Term
| Ipratropium Bromide (Atrovent)-Action |
|
Definition
| Inhibits parasympathetic stimulation by blocking acetylcholine receptors,thus causing bronchodilation |
|
|
Term
| Ipratropium Bromide (Atrovent)-Indications |
|
Definition
| Reversible bronchospasms associated with asthma or COPD |
|
|
Term
| Ipratropium Bromide (Atrovent)-Contraindication |
|
Definition
|
|
Term
| Ipratropium Bromide (Atrovent)-Side Effects |
|
Definition
| Palpitations; dizziness; anxiety; headache; nervousness |
|
|
Term
| Ipratropium Bromide (Atrovent)-Dosage |
|
Definition
|
|
Term
| Lidocane (Xylocaine)-Class |
|
Definition
| Antidysrhythmic / Sodium Channel Blocker |
|
|
Term
| Lidocane (Xylocaine)-Action |
|
Definition
| Depresses depolarization and automaticity in the ventricles of the heart, has ability to increase repolarization |
|
|
Term
| Lidocane (Xylocaine)-Indication |
|
Definition
| V-Fib/Pulseless V-Tach; Stable V-Tach; Wide complex tachycardia of uncertain type |
|
|
Term
| Lidocane (Xylocaine)-Contraindication |
|
Definition
|
|
Term
| Lidocane (Xylocaine)-Side Effects |
|
Definition
| Anxiety; drowsiness; dizziness; confusion; nausea; vomiting; convulsions |
|
|
Term
| Lidocane (Xylocaine)-Dosage |
|
Definition
| Bolus: Initial bolus of 1-1.5 mg/kg IV; additional boluses of 0.5-0.75 mg/kg IV can be repeated at 3-5 min intervals until dysrhythmia has been suppressed or until 3 mg/kg has been administered Drip: After the dysrhythmia has been suppressed, a 2-4 mg/min IV infusion may be started to maintain adequate blood levels |
|
|
Term
|
Definition
| Anticonvulsant and antidysrhythmic |
|
|
Term
| Magnesium Sulfate-Actions |
|
Definition
| Acts as a physiological calcium channel blocker / Blocks neuromuscular transmission |
|
|
Term
| Magnesium Sulfate-Indications |
|
Definition
| Obstetrical: Eclampsia (toxemia of pregnancy) Cardiovascular: Refractory V-Fib and torade de pointes |
|
|
Term
| Magnesium Sulfate-Contraindications |
|
Definition
|
|
Term
| Magnesium Sulfate-Side Effects |
|
Definition
| Flushing; respiratory depression; drowsiness |
|
|
Term
|
Definition
|
|
Term
| Magnesium Sulfate-PCEMS Dosage |
|
Definition
| 2 g in 10 mL normal saline over 1-2 min |
|
|
Term
| Methylprednisone (Solu-Medrol)-Class |
|
Definition
| Corticosteroid and anti-inflammatory |
|
|
Term
| Methylprednisone (Solu-Medrol)-Actions |
|
Definition
| Inhibits many substances that cause inflammation (cytokines, interleukin, interferon) / Suppress immune response |
|
|
Term
| Methylprednisone (Solu-Medrol)-Indications |
|
Definition
| Asthma; COPD; Respiratory distress associated with anaphylaxis; spinal cord injury |
|
|
Term
| Methylprednisone (Solu-Medrol)-Precautions |
|
Definition
| Onset of action may be 2-6 hours, and thus the drug should not be expected to be of use in the critical first hour of an anaphylactic reaction |
|
|
Term
| Methylprednisone (Solu-Medrol)-Side Effects |
|
Definition
| GI bleeding; Prolonged wound healing; Suppression of natural steroids |
|
|
Term
| Methylprednisone (Solu-Medrol)-Dosage |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| CNS depressant; Causes peripheral vasodilation; Decreases sensitivity to pain |
|
|
Term
| Morphine Sulfate-Indications |
|
Definition
| Chest pain associated with ACS unresponsive to nitrates; Pulmonary edema; Severe pain |
|
|
Term
| Morphine Sulfate-Contraindications |
|
Definition
| Hypotension; Head injury; Undiagnosed abdominal pain |
|
|
Term
| Morphine Sulfate-Precaution |
|
Definition
|
|
Term
| Morphine Sulfate-Side Effects |
|
Definition
|
|
Term
|
Definition
| IV: 2-5 mg followed by 2 mg every few minutes until pain is relieved or respiratory depression ensues IM: 5-15 mg |
|
|
Term
| Morphine Sulfate-PCEMS Dosage |
|
Definition
| Cardiac: 2 mg slow IVP every 5 minutes until pain is relieved; max of 10 mg |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Blinds to opiate receptors in the brain, thus reversing any narcotic effects |
|
|
Term
| Naloxone (Narcan)-Indications |
|
Definition
|
|
Term
| Naloxone (Narcan)-Precautions |
|
Definition
| May cause withdrawal effects in patients dependent on narcotics; Short acting; Should be augmented every 5 minutes |
|
|
Term
|
Definition
|
|
Term
| Naloxone (Narcan)-PCEMS Dosage |
|
Definition
| 2 mg slow IVP every 3 minutes as needed; max of 6 mg if < 50 kg 2 mg slow IVP every 3 minutes as needed; max of 10 mg if > 50 kg |
|
|
Term
| Nitroglycerin (Nitrostat)-Class |
|
Definition
|
|
Term
| Nitroglycerin (Nitrostat)-Action |
|
Definition
| Dilates ateries by relaxing smooth muscle, thus reducing cardiac work |
|
|
Term
| Nitroglycerin (Nitrostat)-Indication |
|
Definition
| Chest pain; Pulmonary edema |
|
|
Term
| Nitroglycerin (Nitrostat)-Contraindications |
|
Definition
| Hypotension; Use of erectile dysfunction medication in last 24 hours; Children under 12 years |
|
|
Term
| Nitroglycerin (Nitrostat)-Side Effects |
|
Definition
| Headache; Dizziness; Hypotension |
|
|
Term
| Nitroglycerin (Nitrostat)-Dosage |
|
Definition
| 1 spray SL every 3-5 minutes |
|
|
Term
| Nitroglycerin (Nitrostat)-PCEMS Dosage |
|
Definition
| Spray: 0.4 mg SL every 5 min until nitro drip is established Drip: 10 mcg/min IV; may be increased 5 mcg every 5 min as needed |
|
|
Term
| Procainamide (Pronestyl)-Class |
|
Definition
| Antidysrhythmic / Sodium Channel Blocker used to treat ventricular dysrhythmias, this drug widens the QRS complex and prolongs the Q-T interval |
|
|
Term
| Procainamide (Pronestyl)-Action |
|
Definition
| Reduces the automaticity of the various pacemaker sites in the heart and slows intraventricular conduction, thus elevating the ventricular threshold and suppressing ventricular ectopic activity |
|
|
Term
| Procainamide (Pronestyl)-Indications |
|
Definition
| PSVT; Stable wide-complex tachycardia of unknown origin; A-Fib; WPW syndrome |
|
|
Term
| Procainamide (Pronestyl)-Contraindications |
|
Definition
| High-degree heart blocks; PVCs in conjunction with bradycardia |
|
|
Term
| Procainamide (Pronestyl)-Side Effects |
|
Definition
| Anxiety; Nausea; Convulsions |
|
|
Term
| Procainamide (Pronestyl)-Dosage |
|
Definition
| Initial: 20 mg/min IV until dysrhythmia subsides, Hypotension ensues, QRS complex is widened by 50% of original width, or total of 17 mg/kg has been given |
|
|
Term
| Promethazine (Phenergan)-Class |
|
Definition
| Antihistamine (H1 antagonist) |
|
|
Term
| Promethazine (Phenergan)-Action |
|
Definition
| Blocks H1 receptors, thus producing antiemetic effects |
|
|
Term
| Promethazine (Phenergan)-Indications |
|
Definition
|
|
Term
| Promethazine (Phenergan)-Contraindications |
|
Definition
| Comatose states; Patients who have received a large amount of depressants (including alcohol) |
|
|
Term
| Promethazine (Phenergan)-Side Effect |
|
Definition
|
|
Term
| Promethazine (Phenergan)-Dosage |
|
Definition
|
|
Term
| Promethazine (Phenergan)-PCEMS Dosage |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Sodium Bicarbonate-Actions |
|
Definition
| Combines with excessive acids to form a weak volatile acid, thus increasing pH |
|
|
Term
| Sodium Bicarbonate-Indications |
|
Definition
| Late in management of cardiac arrest / Tricyclic antidepressant overdose / Severe acidosis refractory to hyperventiation |
|
|
Term
| Sodium Bicarbonate-Dosage |
|
Definition
|
|
Term
| Succinylcholine (Anectine)-Class |
|
Definition
| Depolarizing neuromuscular blocker |
|
|
Term
| Succinylcholine (Anectine)-Action |
|
Definition
| Combines with cholinergic receptors in the motor nerves to cause depolarizaton, thus inhibiting neuromuscular transmission which renders the muscles unable to be stimulated by acetylcholine |
|
|
Term
| Succinylcholine (Anectine)-Indications |
|
Definition
| To achieve paralysis to facilitate ET intubation |
|
|
Term
| Succinylcholine (Anectine)-Precaution |
|
Definition
| Paralysis occurs within 1 min and last for approximately 8 min |
|
|
Term
| Succinylcholine (Anectine)-Side Effects |
|
Definition
|
|
Term
| Succinylcholine (Anectine)-Dosage |
|
Definition
|
|
Term
| Succinylcholine (Anectine)-PCEMS Dosage |
|
Definition
|
|
Term
| Thiamine (Vitamin B1)-Class |
|
Definition
|
|
Term
| Thiamine (Vitamin B1)-Action |
|
Definition
| Assists in the conversion of pyruvic acid to acetyl coenzyme A, thus allowng a normal breakdown of glucose |
|
|
Term
| Thiamine (Vitamin B1)-Indications |
|
Definition
| Coma of unknown origin / Alcoholism / Malnourishment / Delirium tremens |
|
|
Term
| Thiamine (Vitamin B1)-Dosage |
|
Definition
| 100 mg IV or IM Before the administration of Dextrose |
|
|
Term
|
Definition
| Vasopressor / Naturally occurring antidiuretic hormone that is a potent vasoconstrictor |
|
|
Term
|
Definition
| Directly stimulates smooth muscle receptors and acts as a potent vasoconstrictor, Antidiuretic hormone |
|
|
Term
|
Definition
| As an alternative pressor to epinephrine in adult cardiac arrest |
|
|
Term
|
Definition
|
|
Term
| Verapamil (Isoptin, Calan)-Class |
|
Definition
|
|
Term
| Verapamil (Isoptin, Calan)-Actions |
|
Definition
| Slows conduction through the AV node; Reduces myocardial oxygen demand due to negative inotropic (contractility) effects; Causes vascular dilation |
|
|
Term
| Verapamil (Isoptin, Calan)-Indications |
|
Definition
| PSVT refractory to adenosine; A-Fib |
|
|
Term
| Verapamil (Isoptin, Calan)-Contraindications |
|
Definition
|
|
Term
| Verapamil (Isoptin, Calan)-Side Effects |
|
Definition
| Nausea; Vomiting; Hypotension; Dizziness |
|
|
Term
| Verapamil (Isoptin, Calan)-Dosage |
|
Definition
| 2.5-5 mg slow IVP; a repeat dose of 5-10 mg IV can be administered after 15-30 min of PSVT does not convert; max of 30 mg in 30 min |
|
|
